TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Return to Work and Living Healthy After Head and Neck Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of laryngea, hypopharyngeal, oropharyngeal, tonsil or base of the tongue cancer within the last six months~* Curative treatment~* Completion of primary and follow-up Treatment~* Fluency in German~* Written informed and voluntary consent~* Psychological distress (Distress Thermometer score \> 4)~* Self-perceived prognosis of employment (SPE score ≥ 1)~Exclusion Criteria:~* Alcohol dependency with physical withdrawal symptoms (CAGE score ≥ 3 and current use of alcohol)~* Acute suicidal tendencies~* Receiving old-age pension or will receive old-age pension within the next 12 months~* Cognitive impairment indicated in the medical records or by the attending doctor~* Being in psychotherapy

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Manualized RELIANCE intervention (Type: EXPERIMENTAL): Return to work and living healthy after head and neck cancer (RELIANCE) is a 2-months group intervention for head and neck cancer patients delivered by a trained psychotherapist and a peer in eight sessions.
- Non-manualized socio-legal counseling (Type: ACTIVE_COMPARATOR): two socio-legal counseling sessions delivered by a social worker

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: A 12 Week Study to Assess Changes in Joint Inflammation Using Ultrasonography in Patients With Rheumatoid Arthritis (RA)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosed with adult-onset Rheumatoid Arthritis (RA) \>6 months and \<3 years~* Active RA~* Must have failed at least one disease modifying Anti Rheumatic Drug (DMARD) treatment~* Subject can have attempted no more than one previous Anti Tumor Necrosis factor (anti-TNF) and discontinued due to drug intolerance~Exclusion Criteria:~* Subject cannot have a second non-inflammatory musculoskeletal condition~* Subject cannot have a diagnosis of any other inflammatory arthritis~* Subject cannot have any previously infected prosthesis~* Subject cannot have arthroplasties in any of the joints assessed in the study~* Subject cannot have a history of chronic infections~* Subject cannot have known Tuberculosis (TB) disease, high risk of acquiring TB, or latent TB infection~* Subject cannot have a history of or current Lymphoproliferative disorder~* Subject cannot have known Human Immunodeficiency Virus (HIV) infection~* Subject cannot have received a live or attenuated vaccine within 8 weeks~* Subject cannot have current or history of malignancy~* Subject cannot have a history of blood disorders~* Subject cannot have a current or recent history of severe, progressive, and/or uncontrolled renal, hepatic, hematological, gastrointestinal, endocrine, pulmonary, cardiac, neurological or cerebral disease~* Subjects must not have a history of adverse reaction to Polyethylene glycol (PEG), a protein medicinal product, or ultrasound gel applied to the skin

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- CZP 200 mg (Type: EXPERIMENTAL): Certolizumab Pegol (CZP) subcutaneous (sc) injections of 400 mg at Weeks 0, 2 and 4, followed by 200 mg at Weeks 6, 8 and 10.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Multimodal Analgesia Versus Routine Care Pain Management

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients undergoing single level MIS-TLIF~* Patients able to provide informed consent~Exclusion Criteria:~* Allergies or other contraindications to medicines in the protocol~* Current liver disease with documented liver function test abnormality~* Current renal disese with documented glomerular filtration rate (GFR) \< 60 mL/min/1.73m2~* Baseline (pre-operative) opioid use greater than 30 mg of morphine equivalents/day~* Active alcohol dependence~* Active illicit drug dependence

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Multimodal analgesia (Type: EXPERIMENTAL): multiple analgesic medications utilized in a synergistic manner to control pain while minimizing side-effects of individual drugs due to decreased doses. This includes pre-operative patient education, intra-operative pain management and post-operative pain protocols.
- Patient Controlled analgesia (Type: ACTIVE_COMPARATOR): Pain management using patient controlled narcotic analgesia.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Motor Control During Rapid Eye Movement (REM) Sleep Behaviour Disorder

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Men and women, 35 to 70 years old, with idiopathic PD (UKPDSBB criteria) with motor fluctuations~* having RBD according to the International Classification of Sleep Disorders, 2nd edition (ICSD-2) criteria~* Eligible to neurosurgical treatment of PD by implantation of intracranial electrodes for the DBS of STN~* Giving a written informed consent~* Affiliated to the French social security program~Exclusion Criteria:~* Atypical or secondary parkinsonian syndrome~* Cognitive impairment which may compromise the understanding and patient's participation to the protocol (Mattis dementia rating scale score ≥ 136)~* Patient under guardianship, trusteeship or judicial protection~* Pregnancy or breastfeeding~* Patient participating to another clinical research study in the same period

- Gender: ALL
- Minimum Age: 35 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Synchronised video-polysomnography (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Imatinib Mesylate Treatment of Patients With Malignant Peripheral Nerve Sheath Tumors

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2/PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion criteria:~* Patients ≥18 years of age~* Histologically documented diagnosis of malignant MPNST~* Unresectable local MPNST or metastatic MPNST and therefore incurable with any conventional multimodality approach Life expectancy of at least 6 months.~Exclusion criteria:~* Patient has received any other investigational agents within 28 days of first day of study drug dosing.~* Chemotherapy and or radiotherapy in between the last 6 weeks before study entry, surgery in between the last 14 days before study entry.~* Female patients who are pregnant or breast feeding or women of child bearing potential who are not using a highly effective method of birth control.~* Known CNS metastases~Other protocol-defined inclusion/exclusion criteria may apply.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- STI571 (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy of NeoThermo-Radio-chemotherapy for LA Rectal Cancer Before Laparoscopic TME: Prospective Phase II Trial

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* 20 years or older~* pathologically confirmed rectal cancer~* Eastern Cooperative Oncology Group performance status 0 to 2~* Candidate of laparoscopic TME~* Optimal bone marrow function~* Locally advanced rectal cancer confirmed by magnetic resonance imaging~Exclusion Criteria:~* Extrapelvic metastasis~* Previous pelvic irradiation~* Current status of pregnant or breast feeding~* Confirmed other malignancy within two years except thyroid cancer

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Thermo-radio-chemotherapy arm (Type: EXPERIMENTAL): Hyperthermia with concurrent chemo-radiation therapy

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Mandibular Furcation II Regeneration

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Subject must be ≥ 20 years~* Subject must have periodontal disease as determined by the World Workshop 2017 criteria~* Subjects must be undergoing periodontal treatment or follow-up and present 1 or more pair of bilateral mandibular molars affected by furcation involvement grade II with PPD \>4 mm, and the furcation fornix must be below a tangential line from the distal to mesial interproximal crestal bone level~* Competent to give consent~Exclusion Criteria:~The following must not be present at the time of enrolment;~* Previous radiotherapy to the jaws, current use of chemotherapy, systemic long-term corticosteroid treatment~* Present or past use of bisphosphonate treatment~* Pregnant or nursing subjects~* Patients classified as \> class 2 according to the ASA (American Society of Anesthesiologists) physical status classification~* Previous surgical therapy of included furcation defects~* Inability to comprehend and respond to the quality of life questionnaire~* Dental restorations or prosthesis involving the furcation area~* Root fractures or suspected infractions~* Caries lesions in the furcation area~* No systemic antibiotic treatment within 3 months prior to intervention

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Regenerative therapy w/BCP and collagen membrane (Type: EXPERIMENTAL): In this arm, treatment of furcation grade II defects includes open flap debridement and regenerative therapy with biphasic calcium phosphate (BCP) and collagen membrane.
- Regenerative therapy w/BCP and enamel matrix proteins (Type: ACTIVE_COMPARATOR): In this arm, treatment of furcation grade II defects includes open flap debridement and regenerative therapy with biphasic calcium phosphate (BCP) and enamel matrix proteins.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Use of Multiple Brain Imaging Modalities (PET and MRS) to Identify Metabolic Abnormalities in Major Depression

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_CONTROL
- Primary Purpose: None
- Time Perspective: CROSS_SECTIONAL
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Meet DSM-IV criteria for Major Depressive Disorder (MDD), Recurrent~* Montgomery-Asberg Depression Rating Scale (MADRS) score \> 18~Exclusion Criteria:~* Any coexisting psychiatric illness other than generalized anxiety disorder, panic disorder, or social/specific phobias~* Any history of substance dependence~* Substance abuse within the past 6 months~* Significant risk of suicide, as defined by score \>4 on item 10 of the MADRS or in the clinical judgment of the study physician~* Any significant medical or neurological condition which is likely to impact the central nervous system and/or affect the results of MRS or PET imaging~* For the subset of unmedicated MDD patients, any psychotropic medications within 4 weeks prior to scanning. For the subgroup of medicated patients, they may be taking a stable dose (i.e., same dose for at least 4 weeks at the time of scanning) of standard antidepressant medications, but may not be taking any other psychotropic medication.~* Inability to give informed consent~* Contraindication to MRI (e.g., pacemaker, ferromagnetic implants in the body)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 55 Years
- Healthy Volunteers: t

Study Arms:
- Depressed, unmedicated (Type: None): Participants with MDD who are not treated with any antidepressant medication
- Depressed, on antidepressant (Type: None): Participants with MDD, currently depressed but on a stable dose of an SSRI antidepressant
- Healthy control (Type: None): Healthy participant with no MDD or other psychiatric condition, matched by age and gender to MDD participants

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Acceptability and Tolerance Study of an Amino Acid Formula with HMOs

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: OTHER
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~Patients well established and stable on Alfamino (or another amino acid formula dependent on feasibility of reaching required numbers) for the dietary management of presumed CMA (no gastrointestinal intolerances on current formula).~Full term infants less than 12 months of age where the amino acid formula is still the sole source of nutrition. Full term infants less than 12 months of age where the amino acid formula is required for 1 week to measure GI tolerance and 1 week of exclusive HMO amino acid formula intake. Thereafter formula intake data will be collected for the remaining 3 weeks and the child can be weaned at this stage.~iWillingly given, written, informed consent from patient or parent/guardian.~Exclusion Criteria:~Partially or fully Breastfed infants. Inability to comply with the study protocol, in the opinion of the investigator.~Previously not tolerated Alfamino without HMOs. More than 12 months old Need an amino acid formula as supplementary use Patients with significant renal or hepatic impairment Change in current medication or use of additional macro/micronutrient supplements during the study period, unless clinically indicated and prescribed by the investigator e.g. thickener, PPIs etc (must be recorded in patient case record file).~Participation in another interventional study within 2 weeks of this study. Introduction of complementary feeding during the study period Caregiver unable to read and write in English (will need to complete 7 1 monthdays of forms at home).

- Gender: ALL
- Minimum Age: 1 Month
- Maximum Age: 12 Months
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Binocular Vision in Monocular Pseudophakia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Participant is willing and able to give informed consent for participation in the study.~* Male or female, aged 18 - 45.~* Cataract operation required in one eye only, either due to the presence of cataract affecting visual function, or in combination with surgery which is likely to cause visually significant cataract.~* Expected visual improvement in operable eye of at least 6/12.~* Fellow eye with a VA of at least 6/9.~* Astigmatism of 1.0D or less.~* Target of emmetropia in the operated eye.~* Intact posterior capsule with planned implantation into the capsular bag.~* IOL power required 10 - 30D.~Exclusion Criteria:~* Pre-existing amblyopia or squint.~* Significant diabetic retinopathy.~* Macular off retinal detachment with metamorphopsia or poor visual prognosis.~* Other macula or ophthalmic pathology affecting macula function resulting in poor visual prognosis.~* Pregnancy, lactating or planned pregnancy during the study period.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 45 Years
- Healthy Volunteers: f

Study Arms:
- Multifocal IOL (Type: EXPERIMENTAL): Phacoemulsification and IOL inserted following cataract surgery
- Standard IOL (Type: ACTIVE_COMPARATOR): Phacoemulsification and IOL inserted following cataract surgery

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Bromocriptine and Pentoxifylline in Ophthalmopathy Autoimmune Treatment

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Women or men~* Between 18 and 45 years~* Autoimmune hyperthyroidism with one year or less of evolution~* No previous treatment~* Mild to moderate ophthalmopathy~Exclusion Criteria:~* Smoking~* Severe ophthalmopathy~* Steroid treatment~* Asthma~* Diabetes or other significant disease~* Creatine \>1.5 mg/dl~* Women with child bearing potential not using a birth control method~* Opthalmologic diseases~* Uncontrolled hypertension~* History of ischemic cardiopathy~* History of stroke~* History of gastrointestinal bleeding

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 45 Years
- Healthy Volunteers: f

Study Arms:
- methimazole (Type: ACTIVE_COMPARATOR): methimazole 30 mg daily during one year
- methimazole, bromocriptine (Type: ACTIVE_COMPARATOR): methimazole 30 mg daily during one year, bromocriptine 5 mg twice a day during one year
- pentoxifylline (Type: ACTIVE_COMPARATOR): methimazol 30 mg daily and pentoxifylline 400 mg twice a day during one year

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy of Amantadine Treatment in COVID-19 Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Age of respondents - 18 years and older.~2. Confirmation of SARS-CoV-2 infection by PCR~3. Hospitalized patient with COVID-19, defined according to the following criteria (all of the following criteria must be present):~   1. radiological (X-ray of klp or TK klp) features of pneumonia,~  2. blood saturation (SaO2) measured at rest in the absence of oxygen \<95%,~  3. it is not necessary to apply on the day of patient enrollment: high-flow oxygen therapy or mechanical ventilation (non-invasive or invasive).~4. Time up to 10 days from the onset of COVID-19 symptoms. The onset of COVID-19 symptoms is the first day on which the first symptom typical for SARS-CoV-2 or COVID-19 infection (in the opinion of the attending physician at the center) occurred, such as: fever, cough, shortness of breath, changes in taste or smell , muscle pain, chest pain, diarrhea, nausea, vomiting, sore throat, nasal congestion.~Exclusion Criteria:~1. Pregnancy or lactation~2. Presence of medical contraindications for inclusion in the examination in the opinion of the attending physician, in particular:~   a) comorbidities: i) clinically significant hepatic or renal insufficiency; ii) epilepsy or seizures (current or history of); iii) psychiatric or somatic diseases (present or in a history of agitation or confusion, delirium syndromes or exogenous psychoses); iv) cardiovascular diseases such as: severe congestive heart failure, cardiomyopathy, myocarditis, grade II-IV AV block, bradycardia, QT prolongation, perceived U waves or family history of congenital long QT syndrome, severe ventricular arrhythmias a history of heart (including torsade de pointes); v) diseases or conditions that significantly reduce the immunity of a patient (e.g. solid organ transplant, bone marrow transplantation (BMT), AIDS, immune biologics and / or high-dose steroids (\> 20 mg prednisone daily).~   b) hypersensitivity to any component of the preparation, c) parallel use of drugs that prolong the QT interval, d) hypokalemia or hypomagnesaemia, e) untreated angle-closure glaucoma, f) use of amantadine currently or in the last 3 months prior to study inclusion; g) participation in another clinical program

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Amantadine (Type: EXPERIMENTAL): None
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy